107 results on '"Aisen P"'
Search Results
2. Lecanemab: Appropriate Use Recommendations
3. Aducanumab: Appropriate Use Recommendations Update
4. Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
5. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
6. Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites
7. Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report
8. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
9. Aducanumab: Appropriate Use Recommendations
10. New Hope for Alzheimer’s Disease
11. The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
12. Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
13. DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3
14. ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE
15. COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE
16. PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT
17. RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASE
18. ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3
19. IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCE
20. BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCE
21. What We Learn from the CTAD 2018 (Clinical Trials Alzheimer’s Disease)
22. Collaborative efforts to prevent Alzheimer's disease
23. EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS
24. CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE
25. GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA
26. RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
27. JPAD IS MOVING FAST
28. REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE
29. ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE
30. THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS
31. CONCLUDING REMARKS
32. THERMODYNAMIC AND ACCESSIBILITY FACTORS IN THE SPECIFIC BINDING OF IRON TO HUMAN TRANSFERRIN
33. The Anion-Binding Functions of Transferrin
34. The Aging Brain - Does Amyloid Matter?
35. EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASE
36. E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS
37. THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS
38. Effect of study partner on the conduct of Alzheimer disease clinical trials
39. Considerations in the Design of Clinical Trials for Cognitive Aging
40. The Validity of Self-Reported Functional Decline Varies by Disease Severity (P04.205)
41. The crystal structure of transferrin binding protein A (TbpA) from Neisseria meningitidis serogroup B in complex with the C-lobe of human transferrin
42. Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial
43. Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease
44. The relative efficiency of time-to-threshold and rate of change in longitudinal data
45. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
46. Report of the task force on designing clinical trials in early (predementia) AD
47. Pre-dementia Alzheimer’s trials: Overview
48. Early Alzheimer’s trials: New developments
49. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization
50. Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.